Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Malfettone, Andrea ^a   Saponaro, Concetta ^a   Paradiso, Angelo ^a   Simone, Giovanni ^a   Mangia, Annita ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Breast cancer; Histological grade; NHERF1; Nottingham prognostic index; Peritumoral vascular invasion; VEGFR1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; SODIUM PROTON EXCHANGER REGULATORY FACTOR 1; TRANSCRIPTION FACTOR TWIST1; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; PHOSPHOPROTEIN; SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CYTOPLASM; FAMILY HISTORY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; NOTTINGHAM PROGNOSTIC INDEX; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHOPROTEINS; PROGNOSIS; SODIUM-HYDROGEN ANTIPORTER; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84858715690     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-106     Document Type: Article

References (46)

1. Mangia A, Malfettone A, Simone G, Darvishian F. Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol 2011, 22(Suppl 1):i24-i30.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. elston & I. O. ellis. Histopathology 1991, 19:403-410. Histopathology. 2002 Sep;41(3A):151,2, discussion 152-3, 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
3. Galea MH, Blamey RW, Elston CE, Ellis IO. The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992, 22(3):207-219. 10.1007/BF01840834, 1391987.
4. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008, 26(19):3153-3158. 10.1200/JCO.2007.15.5986, 18490649.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
6. Ignatiadis M, Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology 2008, 75(2):104-111. 10.1159/000123848, 18544965.
7. Blamey RW. The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 1996, 5:156-157.
8. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005, 65(10):4059-4066. 10.1158/0008-5472.CAN-04-3953, 15899795.
9. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272. 10.1093/jnci/djj052, 16478745.
10. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L, et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008, 9:394. 10.1186/1471-2164-9-394, 2533026, 18717985.
11. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14(9):2601-2608. 10.1158/1078-0432.CCR-07-5026, 18451222.
12. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10(4):R65. 10.1186/bcr2124, 2575538, 18662380.
13. Bonnefoi H, Underhill C, Iggo R, Cameron D. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?. Eur J Cancer 2009, 45(10):1733-1743. 10.1016/j.ejca.2009.04.036, 19477634.
14. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750. 10.1093/jnci/djp082, 2684553, 19436038.
15. Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, et al. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 2010, 222(4):388-399. 10.1002/path.2775, 20922713.
16. Volpi A, Bacci F, Paradiso A, Saragoni L, Scarpi E, Ricci M, et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol 2004, 17(9):1038-1044. 10.1038/modpathol.3800161, 15154006.
17. Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, et al. Biological role of NHERF1 protein expression in breast cancer. Histopathology 2009, 55(5):600-608. 10.1111/j.1365-2559.2009.03424.x, 19912366.
18. Bellizzi A, Malfettone A, Cardone RA, Mangia A. NHERF1/EBP50 in breast cancer: clinical perspectives. Breast Care (Basel) 2010, 5(2):86-90.
19. Mangia A, Malfettone A, Saponaro C, Tommasi S, Simone G, Paradiso A. Human epidermal growth factor receptor 2, na(+)/H(+) exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Hum Pathol 2011, 42(11):1589-1595. 10.1016/j.humpath.2011.01.010, 21496870.
20. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005, 5(10):786-795. 10.1038/nrc1713, 16175178.
21. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007, 4(6):e186. 10.1371/journal.pmed.0040186, 1885450, 17550303.
22. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer 2004, 90(6):1216-1221. 10.1038/sj.bjc.6601452, 2409639, 15026804.
23. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7):927-939. 10.1016/j.cell.2004.06.006, 15210113.
24. Foubert E, De Craene B, Berx G. Key signalling nodes in mammary gland development and cancer. the Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 2010, 12(3):206. 10.1186/bcr2585, 2917026, 20594364.
25. Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, et al. BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol 2009, 24(1):69-76.
26. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 1988, 61(11):2310-2314. 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X, 3284634.
27. Mangia A, Tommasi S, Bruno M, Malfettone A, D'Amico C, Zito FA, et al. Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. Oncol Rep 2010, 23(6):1641-1645.
28. Du Toit RS, Locker AP, Ellis IO, Elston CW, Blamey RW. Evaluation of the prognostic value of triple node biopsy in early breast cancer. Br J Surg 1990, 77(2):163-167. 10.1002/bjs.1800770216, 2317676.
29. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005, 46(1):31-36. 10.1111/j.1365-2559.2005.02045.x, 15656883.
30. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005, 16(Suppl 4):iv14-iv19.
31. Cardone RA, Bellizzi A, Busco G, Weinman, Dell'Aquila ME, Casavola V, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007, 18(5):1768-1780. 10.1091/mbc.E06-07-0617, 1855021, 17332506.
32. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
33. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008, 110(3):465-475. 10.1007/s10549-007-9742-1, 17805961.
34. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011, 19(3):372-386. 10.1016/j.ccr.2011.01.036, 3072410, 21397860.
35. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16(11):1723-1739. 10.1093/annonc/mdi352, 15980158.
36. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011, 127(3):591-599. 10.1007/s10549-010-1028-3, 20623333.
37. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS. Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology 1999, 140(7):2976-2982. 10.1210/en.140.7.2976, 10385389.
38. Maudsley S, Zamah AM, Rahman N, Blitzer JT, Luttrell LM, Lefkowitz RJ, et al. Platelet-derived growth factor receptor association with na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol Cell Biol 2000, 20(22):8352-8363. 10.1128/MCB.20.22.8352-8363.2000, 102142, 11046132.
39. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell 2004, 15(12):5470-5480. 10.1091/mbc.E04-03-0239, 532026, 15469991.
40. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002, 62(24):7203-7206.
41. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12(4):207. 2949637, 20804570.
42. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16(10):1569-1583. 10.1093/annonc/mdi326, 16148022.
43. Mohammed RA, Martin SG, Mahmmod AM, Macmillan RD, Green AR, Paish EC, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol 2011, 223(3):358-365. 10.1002/path.2810, 21171081.
44. Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, et al. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 2011, 24(6):774-785. 10.1038/modpathol.2011.4, 21378756.
45. Sabatier R, Jacquemier J, Bertucci F, Esterni B, Finetti P, Azario F, et al. Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. Eur J Cancer 2011, 47(10):1537-1545. 10.1016/j.ejca.2011.02.002, 21392964.
46. Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Curr Mol Med 2008, 8(6):459-468. 10.2174/156652408785748031, 18781953.